RESUMEN
To show that intravenous immunoglobulin is safe and effective alternative treatment in newborn with iso-immune hemolytic jaundice. This study was carried out in neonatal unit in King Hussein Medical Center [KHMC] and Queen Alia Hospital during two years period of all cases who presented with jaundice either RH or ABO iso-immune jaundice in the first day of life. All patients received phototherapy and intravenous immunoglobulin. There were 91 patients with iso-immune jaundice admitted to the neonatal unit in their first day of life. Eighty five patients out of 91 [93.4%] were due to ABO incompatibility. Six patients out of 91 [6.6%] were due to RH incompatibility. Direct coombs test was positive in all cases of RH incompatibility and in 16 cases of ABO incompatibility. Intravenous immunoglobulin [0.5g/kg] was given to all patients over four hours every 24 hours for three doses. Exchange transfusion was done for one patient only [1%]. Blood transfusion was given for 22 patients out of 91 [24%]. Hospital stay was around 3-4 days in majority of cases. Intravenous immunoglobulin in newborn with ABO or RH hemolytic jaundice is effective in reducing hemolysis, serum bilirubin level and the need for exchange transfusion